Alpine Income Property Trust Announces Fourth Quarter and Full Year 2025 Earnings Release and Conference Call Information

Rhea-AI Summary

Alpine Income Property Trust (NYSE: PINE) will release fourth quarter and full year 2025 financial and operating results after market close on Thursday, February 5, 2026. A conference call to discuss results is scheduled for Friday, February 6, 2026 at 9:00 AM ET with a live webcast available on the company Investor Relations website. Participants are encouraged to register in advance for dial-in details and to join at least 15 minutes early. A replay of the earnings call will be archived on the company website. Contact for investor inquiries is ir@alpinereit.com. The company invests in single-tenant net-leased commercial properties leased predominantly to publicly traded, credit-rated tenants.

News Market Reaction

-7.00%

1 alert

-7.00% News Effect

On the day this news was published, INIS declined 7.00%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Phantech founded: 2018 INIS founded: 1995 RadQual since: 2001 +1 more

4 metrics

Phantech founded 2018 Year Phantech was established

INIS founded 1995 Year International Isotopes Inc. established

RadQual since 2001 RadQual leader in sealed source calibration and reference sources since

Form 10-K year-end 2023 Year ended December 31, 2023 mentioned in safe harbor

Market Reality Check

Price: $0.0885 Vol: Volume 138,387 is below 2...

normal vol

$0.0885 Last Close

Volume Volume 138,387 is below 20-day average 174,904 (relative volume 0.79). normal

Technical Price 16.95 is trading above 200-day MA of 15.3.

Peers on Argus

PINE slipped -0.53% pre‑announcement while peers were mixed: SITC down -2.62%, b...

PINE slipped -0.53% pre‑announcement while peers were mixed: SITC down -2.62%, but WSR, BFS, CBL, and GTY gained between 0.51% and 1.01%, suggesting stock‑specific trading rather than a broad REIT‑retail move.

Historical Context

5 past events · Latest: Jan 02 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 02	Transaction activity update	Positive	+0.4%	Record 2025 investment activity and strong Q4 cash yields.
Dec 01	Transactions & preferred	Neutral	+0.8%	YTD acquisitions, loans, dispositions and preferred equity raise.
Nov 20	Retail acquisition	Positive	+1.6%	Purchase of fully leased Walmart/TJ Maxx‑anchored center.
Nov 18	Dividend declaration	Positive	+0.8%	Q4 2025 common and preferred dividend declarations.
Nov 12	Sam’s Club acquisition	Positive	+1.6%	Acquisition of long‑tenured Sam’s Club in Houston.

Pattern Detected

Recent operational and capital markets news has generally coincided with modestly positive next‑day moves.

Recent Company History

Over the last few months, Alpine Income Property Trust has focused on portfolio growth and capital markets activity. It reported record $277.7M 2025 investment activity and strong Q4 deployments at double‑digit initial cash yields. Prior updates highlighted acquisitions such as a $20.7M Walmart/TJ Maxx center and a $15.4M Sam’s Club asset, plus a $50.0M 8.00% Series A preferred equity raise. Occupancy has remained around 99.4% with long weighted average lease terms, and these announcements have typically been met with small positive price reactions.

Market Pulse Summary

The stock moved -7.0% in the session following this news. A negative reaction despite a routine earn...

Analysis

The stock moved -7.0% in the session following this news. A negative reaction despite a routine earnings‑call scheduling notice would fit a pattern where broader fundamentals and capital structure weigh on sentiment. Recent SEC filings showed a quarterly net loss, higher interest costs, and a new 8.00% preferred layer, while insider activity over 90 days reflected net selling of 1,000 shares. With prior “conferences,earnings” notices historically tied to small average moves of about 0.71%, a sharp decline could reflect investors refocusing on these underlying concerns.

Key Terms

theranostics, radiopharmaceutical, Cobalt-60, PET, +4 more

8 terms

theranostics medical

"radioisotope API supply for 3rd party theranostics clients."

Theranostics combines a medical test with a targeted treatment so the same approach both finds disease and delivers therapy—like a guided missile that first locates a target then destroys it. For investors, it matters because pairing diagnosis and therapy can speed identification of patients who will benefit, reduce wasted treatments, create dual revenue streams (tests plus drugs), and alter regulatory and reimbursement dynamics that affect commercial potential.

radiopharmaceutical medical

"supplies generic sodium iodide I-131 radiopharmaceutical drug product for hyperthyroidism"

A radiopharmaceutical is a special type of medicine that contains a small amount of radioactive material, used primarily for medical imaging or treatment. It can be thought of as a tiny, targeted signal that helps doctors see inside the body or deliver therapy directly to affected areas. For investors, understanding radiopharmaceuticals is important because they represent a growing field within healthcare, driven by advancements in diagnostics and personalized treatments.

Cobalt-60 medical

"The Company also manufactures Cobalt-60 sealed source products and provides contract"

Cobalt-60 is a radioactive form of the metal cobalt that gives off powerful gamma rays used as a controlled source of radiation for medical treatments, sterilizing medical tools, and inspecting heavy equipment. Investors care because its production, transport, regulation and safe storage create commercial markets, supply risks and regulatory costs for companies involved in medical devices, industrial testing and nuclear materials—similar to how a rare ingredient can shape multiple supply chains and safety rules.

PET medical

"theranostic phantoms for PET, SPECT, CT, optical (FLI/BLI), MRI, radioluminescence,"

Positron emission tomography (PET) is a medical imaging test that creates a live map of how organs and tissues are working by tracking a tiny, safe amount of radioactive tracer inside the body. For investors, PET matters because it’s often used in clinical trials and diagnosis to show whether a drug or treatment is affecting disease — think of it as a performance meter that can speed regulatory decisions, change market forecasts, and affect a product’s commercial value.

SPECT medical

"theranostic phantoms for PET, SPECT, CT, optical (FLI/BLI), MRI, radioluminescence,"

SPECT (Single Photon Emission Computed Tomography) is a medical imaging technique that uses a very small amount of radioactive material and a rotating camera to create three-dimensional pictures of how blood and tissues are functioning inside organs. For investors, SPECT matters because it is used to support clinical diagnoses, trial endpoints, device or drug approvals, and market demand for imaging equipment and tracers—similar to how a multi‑angle camera reveals a hidden object’s shape and condition.

MRI medical

"theranostic phantoms for PET, SPECT, CT, optical (FLI/BLI), MRI, radioluminescence,"

Magnetic resonance imaging (MRI) is a medical scan that uses magnetic fields and radio waves to create detailed pictures of the inside of the body, like a high-resolution camera for tissues and organs. Investors care because MRI drives demand for imaging machines, hospital services, diagnostics and can be central to clinical trial results and regulatory decisions—changes in MRI use or technology can affect revenue, capital spending and reimbursement in healthcare and medical device markets.

systemic targeted radionuclide therapy (TRT) medical

"magnetic particle imaging, systemic targeted radionuclide therapy (TRT) and external"

Systemic targeted radionuclide therapy (TRT) is a cancer treatment that delivers tiny radioactive particles through the bloodstream attached to molecules that seek out and stick to tumor cells, like a guided missile or a labeled package finding a specific address. It matters to investors because TRT can create new therapeutic revenue streams but carries clear regulatory, safety, and manufacturing risks; clinical success, approval, and pricing determine commercial value.

external beam radiation therapy (XRT) medical

"systemic targeted radionuclide therapy (TRT) and external beam radiation therapy (XRT)."

External beam radiation therapy (XRT) is a cancer treatment that uses a machine outside the body to aim high-energy rays at a tumor, similar to using a focused spotlight to heat and weaken a single spot without cutting. For investors, XRT matters because its effectiveness, side effects, delivery technology, and adoption influence demand for medical devices, hospital spending, drug combinations, regulatory approvals and reimbursement decisions that drive revenue and risk for healthcare companies.

AI-generated analysis. Not financial advice.

WINTER PARK, Fla., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Alpine Income Property Trust, Inc. (NYSE: PINE) (the “Company”) announced today that it will report its financial and operating results for the fourth quarter and full year 2025 after the market closes on Thursday, February 5, 2026. A conference call to discuss its financial and operating results is scheduled for Friday, February 6, 2026 at 9:00 AM ET.

A live webcast of the call will be available on the Investor Relations page of the Company’s website at www.alpinereit.com or at the link provided in the event details below. To access the call by phone, please go to the link provided in the event details below and you will be provided with dial-in details.

Event Details:
Webcast:	https://edge.media-server.com/mmc/p/29ccafvb
Registration:	https://register-conf.media-server.com/register/BI744f656bb5534f569cf60d82d5a4aa72

We encourage participants to register and dial into the conference call at least fifteen minutes ahead of the scheduled start time. A replay of the earnings call will be archived and available online through the Investor Relations section of the Company’s website at www.alpinereit.com.

About Alpine Income Property Trust, Inc.

Alpine Income Property Trust, Inc. (NYSE: PINE) is a publicly traded real estate investment trust that seeks to deliver attractive risk-adjusted returns and dependable cash dividends by investing in, owning and operating a portfolio of single tenant net leased commercial income properties that are predominately leased to high-quality publicly traded and credit-rated tenants.

We encourage you to review our most recent investor presentation which is available on our website at http://www.alpinereit.com.

Contact:
Investor Relations
ir@alpinereit.com

FAQ

When will Alpine Income Property Trust (PINE) report Q4 and full year 2025 results?

The company will report results after market close on February 5, 2026.

What is the date and time of the Alpine Income Property Trust (PINE) earnings call for Q4 2025?

The conference call is scheduled for February 6, 2026 at 9:00 AM ET.

Where can investors access the Alpine Income Property Trust (PINE) live webcast for the earnings call?

The live webcast will be available on the company Investor Relations website at www.alpinereit.com or via the provided event webcast link.

How do I register or get dial-in details for the Alpine Income Property Trust (PINE) earnings call?

Register using the event registration link provided in the announcement to receive dial-in details and joining instructions.

Will Alpine Income Property Trust (PINE) provide a replay of the Q4 2025 earnings call?

Yes. A replay will be archived and available through the Investor Relations section of www.alpinereit.com.

Who should investors contact for questions about Alpine Income Property Trust (PINE) investor relations?

Investor inquiries can be directed to the listed contact email: ir@alpinereit.com.